ArticleCureus2024
Roxadustat-Induced Central Hypothyroidism Masked by Uremia at the Initiation of Hemodialysis: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Initial side effects of roxadustat on thyroid function in patients undergoing hemodialysis.Renal failure · 2026Article
- Understanding the Drivers of Hypothyroidism in Patients Undergoing Chronic Hemodialysis.Diagnostics (Basel, Switzerland) · 2026Article
- Roxadustat as a Hypoxia-Mimetic Agent: Erythropoietic Mechanisms, Bioanalytical Detection, and Regulatory Considerations in Sports Medicine.Current issues in molecular biology · 2025Review
- Roxadustat Activates Thyroid Hormone Receptors α and β at Clinically Relevant Concentrations.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a novel class of orally administered medications for renal anemia in patients with end-stage renal disease (ESRD). Roxadustat, a HIF-PHI, has a structure similar to that of triiodothyronine and may work as an agonist for thyroid hormone receptor-beta in the pituitary gland and/or hypothalamus. Therefore, roxadustat may cause central hypothyroidism due to suppressing thyroid-stimulating hormone (TSH) release in the pituitary gland and/or thyrotropin-releasing hormone release in the hypothalamus. On the other hand, some symptoms of uremia and hypothyroidism, such as fatigue, anorexia, or edema, are common. Therefore, hypothyroidism might be masked by uremia in patients with ESRD. We herein report the case of a 74-year-old man with roxadustat-induced central hypothyroidism masked by uremia at the initiation of hemodialysis. After stopping roxadustat medication without thyroid hormone replacement therapy, the patient's TSH, free triiodothyronine, and free tetraiodothyronine levels returned to the normal range rapidly, and uremic-like symptoms such as anorexia and physical fatigue also gradually recovered. The number of ESRD patients undergoing treatment for renal anemia with roxadustat might increase in the future; hence, close attention to roxadustat-induced central hypothyroidism in ESRD patients with uremia at the initiation of hemodialysis is essential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.